GVD

GVD is a chemotherapy regimen used primarily for the treatment of relapsed or refractory Hodgkin lymphoma. It consists of three drugs: gemcitabine, vinorelbine, and Doxil (a pegylated liposomal formulation of doxorubicin). The regimen is administered on days 1 and 8 of a 21-day cycle with different dosing based on patient status: For transplant-naive patients: - Gemcitabine: 1000 mg/m² IV infusion - Vinorelbine: 20 mg/m² IV bolus - Doxil (liposomal doxorubicin): 15 mg/m² IV infusion For post-transplant patients: - Gemcitabine: 800 mg/m² IV infusion - Vinorelbine: 15 mg/m² IV bolus - Doxil (liposomal doxorubicin): 10 mg/m² IV infusion GVD has demonstrated significant efficacy in treating relapsed Hodgkin lymphoma, with reported overall response rates of 70%, complete remission rates of 19%, and favorable survival rates, particularly in transplant-naive patients receiving subsequent autologous transplant. It has shown activity even in heavily pretreated patients who failed prior transplant. The dose-limiting toxicities differ between patient populations (mucositis for transplant-naive, febrile neutropenia for post-transplant). Other common adverse events include anemia, neutropenia, and fatigue. The regimen is generally considered well-tolerated compared to other salvage regimens. Recent developments include combinations with immune checkpoint inhibitors (pembro-GVD showing high response rates) and dexamethasone (GVDexa showing 80% response rate). GVD is described as an effective outpatient-compatible salvage therapy option with a favorable toxicity profile.

Other names

GVD regimen